DERMABET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DERMABET (DERMABET).
Betamethasone dipropionate is a corticosteroid that diffuses across cell membranes and binds to glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. It induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and decreasing the synthesis of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Betamethasone dipropionate is metabolized primarily in the liver via ester hydrolysis to betamethasone, which is further metabolized via CYP3A4-mediated oxidation and glucuronidation. |
| Excretion | Renal (60-70% as unchanged drug and metabolites), biliary/fecal (30-40%) |
| Half-life | Terminal elimination half-life: 3-4 hours; prolonged in hepatic impairment |
| Protein binding | 90-95% bound to albumin |
| Volume of Distribution | 0.5-0.8 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 70-90%; Topical: minimal systemic absorption (approximately 1-2% with intact skin) |
| Onset of Action | Oral: 30-60 minutes; Topical: 2-4 hours for anti-inflammatory effect |
| Duration of Action | Oral: 8-12 hours; Topical: 12-24 hours with occlusive dressing |
Apply a thin layer to affected area once or twice daily. Maximum 50 g per week.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | Apply a thin layer to affected area once daily. Use lowest effective strength for shortest duration. |
| Geriatric use | Use with caution; apply sparingly to small areas for shortest duration due to increased skin atrophy risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DERMABET (DERMABET).
| Breastfeeding | Corticosteroids are excreted in breast milk. M/P ratio for betamethasone is approximately 0.3. At maternal doses ≤40 mg/day, minimal systemic effects in the infant; higher doses may require monitoring for growth and adrenal suppression. Weigh benefits against risks. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Corticosteroids are associated with cleft palate (1-2% increased risk). Second and third trimesters: Increased risk of intrauterine growth restriction, adrenal suppression in the fetus, and preterm delivery with chronic high-dose use. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to betamethasone dipropionate or any component of the formulation; untreated bacterial, fungal, or viral infections at the application site; perioral dermatitis; acne vulgaris; rosacea.
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and unmask latent diabetes. Use on face or intertriginous areas increases risk of adverse effects. Avoid prolonged use or application to large surface areas, especially in children. Do not use with occlusive dressings unless directed. Monitor for local skin atrophy, telangiectasias, and striae. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, blood glucose (especially in diabetics), signs of infection. Fetal monitoring includes serial ultrasound for growth restriction and adrenal function (e.g., fetal adrenal suppression). Consider monitoring for maternal hypothalamic-pituitary-adrenal axis suppression with prolonged use. |
| Fertility Effects | No established adverse effects on fertility in humans. Corticosteroids may disrupt ovulation at high doses but rarely impact fertility at therapeutic topical doses. |